abs102.txt	purpose		lung	cancer	is	the	leading	cause	of	cancer-related	death	non-small	celllung	(nsclc)	accounts	for	85%	all	cancers	and	over	60%	expresswild-type	egfr	(wtegfr)	however	tyrosine	kinase	inhibitors	(tkis)	havelimited	effect	in	most	patients	with	wtegfr	tumors	we	previously	identifiedmertk	as	a	potential	therapeutic	target	nsclc	developedmrx-2843	novel	mertk-selective	inhibitor	favorable	properties	forclinical	translation	goal	this	study	was	to	determine	whether	mertk	andegfr	combination	therapy	could	provide	antitumor	efficacy	againstwtegfr	experimental	design	an	unbiased	screen	378	wasconducted	identify	synergistic	interactions	mrx-2843	biochemical	andtherapeutic	effects	were	determined	vitro	vivo	results	numerousirreversible	tkis	including	co-1686	osimertinib	synergized	withmrx-2843	inhibit	cell	expansion	irrespective	driver	oncogenestatus	inhibited	anderbb2/erbb3	decreased	downstream	pi3k-akt	mapk-erk	aurora	(aurk)signaling	more	effectively	than	single	agents	inhibition	pi3k	akt	or	aurk	but	not	mek	tumor	suggestingtheir	roles	key	redundant	resistance	pathways	treatment	andco-1686	prevented	xenograft	growth	while	had	limitedeffect	durable	even	after	combinationtherapy	stopped	conclusions	our	data	support	application	incombination	irreversible	tki	strategy	ofpatients	clin	res	1-13	Â©2018	aacr
